Archive

Canadian Amyloidosis Summit – Toronto ON

Downtown Hyatt Regency

Please join us for the Canadian Amyloidosis Summit. This exciting hybrid event will provide important information and updates on the management of amyloidosis and feature national and international experts. It is a 2-day event, October 18-20 2024, at the Downtown Hyatt Regency in Toronto Ontario,...

2024 Toronto Complement Conference

Peter Gilgan Centre for Research and Learning

Over the past two decades complement research has seen a breathtaking development, and progress related to complement-mediated diseases has resulted in life-transforming advancements in patient management. Nevertheless, research and clinical translation thereof are still only at their beginnings, and there is a tremendous opportunity for...

CHS Awards Gala-December 8, 2024, San Diego, CA

Luce Loft 1037 J Street, San Diego, United States

Time to mix and mingle with your peers and celebrate achievements in Canadian hematology. Where: Luce Lofts - 1037 J Street, San Diego, CA Date: Sunday, December 8, 2024 Time: 7:30-10:00pm LOCAL TIME Dress code: business casual All CHS members attend at no cost. REGISTER...

ISLH 2025 the 38th International Symposium on Technological Innovations in Laboratory Hematology – Halifax, Nova Scotia

Halifax Cenvention Centre Halifax, Nova Scotia

ISLH 2025 CALL FOR ABSTRACTS On behalf of the International Society for Laboratory Hematology (ISLH) and our partner organizations: North American Specialized Coagulation Laboratory Association (NASCOLA), Accreditation Canada (AC), and the Institute of Quality Management in Healthcare (IQMH), we are pleased to invite you and...

The Next Frontier in Immunotherapy for Multiple Myeloma: What Will BCMA Targeting Mean for Our Relapsed/Refractory Patients? Video Activity

Virtual , Canada

Key learning objectives:
∙ Explain the mechanism of action of BCMA-targeted strategies for the treatment of relapsed/refractory multiple myeloma (RRMM)
∙ Evaluate the clinical evidence with BCMA-targeted approaches for the treatment of RRMM
∙ Discuss practical considerations, including key differences between BCMA-targeted treatments, that may inform their use in RRMM